A Case of Nonfunctioning Pituitary Carcinoma That Responded to Temozolomide Treatment
Pituitary carcinoma is a rare malignancy and is difficult to manage. Pituitary carcinomas commonly produce either PRL or ACTH, but some do not produce pituitary hormones. The alkylating reagent temozolomide (TMZ) was recently shown to be effective as a treatment for pituitary carcinoma. Most of the...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | Case Reports in Endocrinology |
| Online Access: | http://dx.doi.org/10.1155/2012/645914 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832560327503380480 |
|---|---|
| author | Haruko Morokuma Takao Ando Takuya Hayashida Ichiro Horie Naoko Inoshita Fumi Murata Ikuko Ueki Kan Nakamura Misa Imaizumi Toshiro Usa Atsushi Kawakami |
| author_facet | Haruko Morokuma Takao Ando Takuya Hayashida Ichiro Horie Naoko Inoshita Fumi Murata Ikuko Ueki Kan Nakamura Misa Imaizumi Toshiro Usa Atsushi Kawakami |
| author_sort | Haruko Morokuma |
| collection | DOAJ |
| description | Pituitary carcinoma is a rare malignancy and is difficult to manage. Pituitary carcinomas commonly produce either PRL or ACTH, but some do not produce pituitary hormones. The alkylating reagent temozolomide (TMZ) was recently shown to be effective as a treatment for pituitary carcinoma. Most of the published reports of TMZ use in pituitary carcinoma cases were against hormone-producing carcinomas. Only a few patients with a nonfunctioning pituitary carcinoma treated with TMZ have been reported. Here we describe our treatment of a patient with nonfunctioning pituitary carcinoma and a background of multiple endocrine neoplasia type 1. The pituitary carcinoma was accompanied by meningeal dissemination with cerebral and L1 spinal bone metastasis. The patient received continuous dosing of TMZ along with external radiation, followed by standard dosing of TMZ. There was an apparent antitumor response seen in MRI. MGMT, an enzyme antagonized by TMZ, was negative in the tumor. The therapeutic efficacy of TMZ and dosing schedules of TMZ in pituitary carcinoma are discussed. |
| format | Article |
| id | doaj-art-8e766e05bb654bf38ac1de753335ec08 |
| institution | Kabale University |
| issn | 2090-6501 2090-651X |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Endocrinology |
| spelling | doaj-art-8e766e05bb654bf38ac1de753335ec082025-02-03T01:27:52ZengWileyCase Reports in Endocrinology2090-65012090-651X2012-01-01201210.1155/2012/645914645914A Case of Nonfunctioning Pituitary Carcinoma That Responded to Temozolomide TreatmentHaruko Morokuma0Takao Ando1Takuya Hayashida2Ichiro Horie3Naoko Inoshita4Fumi Murata5Ikuko Ueki6Kan Nakamura7Misa Imaizumi8Toshiro Usa9Atsushi Kawakami10First Department of Medicine, Nagasaki University Graduates School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki 852-8501, JapanFirst Department of Medicine, Nagasaki University Graduates School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki 852-8501, JapanFirst Department of Medicine, Nagasaki University Graduates School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki 852-8501, JapanFirst Department of Medicine, Nagasaki University Graduates School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki 852-8501, JapanDepartment of Pathology, Toranomon Hospital, 2-2-2 Toranomon, Minato-ku, Tokyo 105-8470, JapanFirst Department of Medicine, Nagasaki University Graduates School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki 852-8501, JapanFirst Department of Medicine, Nagasaki University Graduates School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki 852-8501, JapanFirst Department of Medicine, Nagasaki University Graduates School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki 852-8501, JapanFirst Department of Medicine, Nagasaki University Graduates School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki 852-8501, JapanFirst Department of Medicine, Nagasaki University Graduates School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki 852-8501, JapanFirst Department of Medicine, Nagasaki University Graduates School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki 852-8501, JapanPituitary carcinoma is a rare malignancy and is difficult to manage. Pituitary carcinomas commonly produce either PRL or ACTH, but some do not produce pituitary hormones. The alkylating reagent temozolomide (TMZ) was recently shown to be effective as a treatment for pituitary carcinoma. Most of the published reports of TMZ use in pituitary carcinoma cases were against hormone-producing carcinomas. Only a few patients with a nonfunctioning pituitary carcinoma treated with TMZ have been reported. Here we describe our treatment of a patient with nonfunctioning pituitary carcinoma and a background of multiple endocrine neoplasia type 1. The pituitary carcinoma was accompanied by meningeal dissemination with cerebral and L1 spinal bone metastasis. The patient received continuous dosing of TMZ along with external radiation, followed by standard dosing of TMZ. There was an apparent antitumor response seen in MRI. MGMT, an enzyme antagonized by TMZ, was negative in the tumor. The therapeutic efficacy of TMZ and dosing schedules of TMZ in pituitary carcinoma are discussed.http://dx.doi.org/10.1155/2012/645914 |
| spellingShingle | Haruko Morokuma Takao Ando Takuya Hayashida Ichiro Horie Naoko Inoshita Fumi Murata Ikuko Ueki Kan Nakamura Misa Imaizumi Toshiro Usa Atsushi Kawakami A Case of Nonfunctioning Pituitary Carcinoma That Responded to Temozolomide Treatment Case Reports in Endocrinology |
| title | A Case of Nonfunctioning Pituitary Carcinoma That Responded to Temozolomide Treatment |
| title_full | A Case of Nonfunctioning Pituitary Carcinoma That Responded to Temozolomide Treatment |
| title_fullStr | A Case of Nonfunctioning Pituitary Carcinoma That Responded to Temozolomide Treatment |
| title_full_unstemmed | A Case of Nonfunctioning Pituitary Carcinoma That Responded to Temozolomide Treatment |
| title_short | A Case of Nonfunctioning Pituitary Carcinoma That Responded to Temozolomide Treatment |
| title_sort | case of nonfunctioning pituitary carcinoma that responded to temozolomide treatment |
| url | http://dx.doi.org/10.1155/2012/645914 |
| work_keys_str_mv | AT harukomorokuma acaseofnonfunctioningpituitarycarcinomathatrespondedtotemozolomidetreatment AT takaoando acaseofnonfunctioningpituitarycarcinomathatrespondedtotemozolomidetreatment AT takuyahayashida acaseofnonfunctioningpituitarycarcinomathatrespondedtotemozolomidetreatment AT ichirohorie acaseofnonfunctioningpituitarycarcinomathatrespondedtotemozolomidetreatment AT naokoinoshita acaseofnonfunctioningpituitarycarcinomathatrespondedtotemozolomidetreatment AT fumimurata acaseofnonfunctioningpituitarycarcinomathatrespondedtotemozolomidetreatment AT ikukoueki acaseofnonfunctioningpituitarycarcinomathatrespondedtotemozolomidetreatment AT kannakamura acaseofnonfunctioningpituitarycarcinomathatrespondedtotemozolomidetreatment AT misaimaizumi acaseofnonfunctioningpituitarycarcinomathatrespondedtotemozolomidetreatment AT toshirousa acaseofnonfunctioningpituitarycarcinomathatrespondedtotemozolomidetreatment AT atsushikawakami acaseofnonfunctioningpituitarycarcinomathatrespondedtotemozolomidetreatment AT harukomorokuma caseofnonfunctioningpituitarycarcinomathatrespondedtotemozolomidetreatment AT takaoando caseofnonfunctioningpituitarycarcinomathatrespondedtotemozolomidetreatment AT takuyahayashida caseofnonfunctioningpituitarycarcinomathatrespondedtotemozolomidetreatment AT ichirohorie caseofnonfunctioningpituitarycarcinomathatrespondedtotemozolomidetreatment AT naokoinoshita caseofnonfunctioningpituitarycarcinomathatrespondedtotemozolomidetreatment AT fumimurata caseofnonfunctioningpituitarycarcinomathatrespondedtotemozolomidetreatment AT ikukoueki caseofnonfunctioningpituitarycarcinomathatrespondedtotemozolomidetreatment AT kannakamura caseofnonfunctioningpituitarycarcinomathatrespondedtotemozolomidetreatment AT misaimaizumi caseofnonfunctioningpituitarycarcinomathatrespondedtotemozolomidetreatment AT toshirousa caseofnonfunctioningpituitarycarcinomathatrespondedtotemozolomidetreatment AT atsushikawakami caseofnonfunctioningpituitarycarcinomathatrespondedtotemozolomidetreatment |